Database : MEDLINE
Search on : Cromolyn and Sodium [Words]
References found : 4336 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 434 go to page                         

  1 / 4336 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29485888
[Au] Autor:Warnken ZN; Smyth HDC; Davis DA; Weitman S; Kuhn JG; Williams RO
[Ad] Address:Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy , University of Texas at Austin , Austin , Texas 78712 , United States.
[Ti] Title:Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts.
[So] Source:Mol Pharm;, 2018 Mar 06.
[Is] ISSN:1543-8392
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Effective targeting of nasal spray deposition could improve local, systemic, and CNS drug delivery; however, this has proven to be difficult due to the anatomical features of the nasal cavity, including the nasal valve and turbinate structures. Furthermore, nasal cavity geometries and dimensions vary between individuals based on differences in their age, gender, and ethnicity. The effect of patient-specific administration parameters was evaluated for their ability to overcome the barriers of targeted nasal drug delivery. The nasal spray deposition was evaluated in 10 3D-printed nasal cavity replicas developed based on the CT-scans of five pediatric and five adult subjects. Cromolyn sodium nasal solution, USP, modified with varying concentrations of hypromellose was utilized as a model nasal spray to evaluate the deposition pattern from formulations producing a variety of plume angles. A central composite design of experiments was implemented using the formulation with the narrowest plume angle to determine the patient-specific angle for targeting the turbinate region in each individual. The use of the patient-specific angle with this formulation significantly increased the turbinate deposition efficiency compared to that found for all subjects using an administration angle of 30°, around 90% compared to about 73%. Generally, we found turbinate deposition increased with decreases in the administration angle. Deposition to the upper regions of the replica was poor with any formulation or administration angle tested. Effective turbinate targeting of nasal sprays can be accomplished with the use of patient-specific administration parameters in individuals. Further research is required to see if these parameters can be device-controlled for patients and if other regions can be effectively targeted with other nasal devices.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher
[do] DOI:10.1021/acs.molpharmaceut.7b00702

  2 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28744120
[Au] Autor:Chakraborty S; Kar N; Kumari L; De A; Bera T
[Ad] Address:Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India.
[Ti] Title:Inhibitory effect of a new orally active cedrol-loaded nanostructured lipid carrier on compound 48/80-induced mast cell degranulation and anaphylactic shock in mice.
[So] Source:Int J Nanomedicine;12:4849-4868, 2017.
[Is] ISSN:1178-2013
[Cp] Country of publication:New Zealand
[La] Language:eng
[Ab] Abstract:BACKGROUND: Type I hypersensitivity is an allergic reaction characterized by the overactivity of the immune system provoked by normally harmless substances. Glucocorticoids, anti-histamines, or mast cell stabilizers are the choices of treatment for type I hypersensitivity. Even though these drugs have the anti-allergic effect, they can have several side effects in prolong use. Cedrol is the main bioactive compound of with anti-tumor, anti-oxidative, and platelet-activating factor inhibiting properties. METHODS: In this study, the preparation and anti-anaphylactic effect of cedrol-loaded nanostructured lipid carriers (NLCs) were evaluated. NLCs were prepared using Compritol 888 ATO and triolein as lipid phase and vitamin E d-α-tocopherylpolyethyleneglycol 1000 succinate, soya lecithin, and sodium deoxycholate as nanoparticle stabilizers. RESULTS: The average diameter of cedrol-NLCs (CR-NLCs) was 71.2 nm (NLC-C ) and 91.93 nm (NLC-C ). The particle had negative zeta potential values of -31.9 mV (NLC-C ) and -44.5 mV (NLC-C ). Type I anaphylactoid reaction in the animal model is significantly reduced by cedrol and cedrol-NLC. This in vivo activity of cedrol resulted that cedrol suppressed compound 48/80-induced peritoneal mast cell degranulation and histamine release from mast cells. Furthermore, compound 48/80-evoked Ca uptake into mast cells was reduced in a dose-dependent manner by cedrol and cedrol-NLC. Studies confirmed that the inhibition of type I anaphylactoid response in vivo in mice and compound 48/80-induced mast cell activation in vitro are greatly enhanced by the loading of cedrol into the NLCs. The safety of cedrol and CR-NLC was evaluated as selectivity index (SI) with prednisolone and cromolyn sodium as positive control. SI of CR-NLC-C was found to be 11.5-fold greater than both prednisolone and cromolyn sodium. CONCLUSION: Administration of CR-NLC 24 hours before the onset of anaphylaxis can prevent an anaphylactoid reaction. NLCs could be a promising vehicle for the oral delivery of cedrol to protect anaphylactic reactions.
[Mh] MeSH terms primary: Anaphylaxis/drug therapy
Drug Carriers/chemistry
Mast Cells/drug effects
Nanostructures/administration & dosage
Terpenes/administration & dosage
[Mh] MeSH terms secundary: Administration, Oral
Animals
Cell Degranulation/drug effects
Dose-Response Relationship, Drug
Drug Carriers/administration & dosage
Fatty Acids
Female
Histamine Release/drug effects
Lipids/administration & dosage
Lipids/chemistry
Male
Mast Cells/physiology
Mice, Inbred BALB C
Nanoparticles/chemistry
Nanostructures/chemistry
Terpenes/pharmacology
Triolein/chemistry
Vitamin E/chemistry
p-Methoxy-N-methylphenethylamine/adverse effects
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Drug Carriers); 0 (Fatty Acids); 0 (Lipids); 0 (Terpenes); 122-32-7 (Triolein); 1406-18-4 (Vitamin E); 18641-57-1 (glyceryl behenate); 4091-50-3 (p-Methoxy-N-methylphenethylamine); 63ZM9703BO (cedrol); O03S90U1F2 (tocophersolan)
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:170727
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S132114

  3 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28471519
[Au] Autor:Hughes EL; Becker F; Flower RJ; Buckingham JC; Gavins FNE
[Ad] Address:Centre for Brain Sciences, Department of Medicine, Imperial College London, London, W12 0NN, UK.
[Ti] Title:Mast cells mediate early neutrophil recruitment and exhibit anti-inflammatory properties via the formyl peptide receptor 2/lipoxin A receptor.
[So] Source:Br J Pharmacol;174(14):2393-2408, 2017 Jul.
[Is] ISSN:1476-5381
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND AND PURPOSE: In recent years, studies have focused on the resolution of inflammation, which can be achieved by endogenous anti-inflammatory agonists such as Annexin A1 (AnxA1). Here, we investigated the effects of mast cells (MCs) on early LPS-induced neutrophil recruitment and the involvement of the AnxA1-formyl peptide receptor 2/ALX (FPR2/ALX or lipoxin A receptor) pathway. EXPERIMENTAL APPROACH: Intravital microscopy (IVM) was used to visualize and quantify the effects of LPS (10 µg per mouse i.p.) on murine mesenteric cellular interactions. Furthermore, the role that MCs play in these inflammatory responses was determined in vivo and in vitro, and effects of AnxA1 mimetic peptide Ac2-26 were assessed. KEY RESULTS: LPS increased both neutrophil endothelial cell interactions within the mesenteric microcirculation and MC activation (determined by IVM and ruthenium red dye uptake), which in turn lead to the early stages of neutrophil recruitment. MC recruitment of neutrophils could be blocked by preventing the pro-inflammatory activation (using cromolyn sodium) or enhancing an anti-inflammatory phenotype (using Ac2-26) in MCs. Furthermore, MCs induced neutrophil migration in vitro, and MC stabilization enhanced the release of AnxA1 from neutrophils. Pharmacological approaches (such as the administration of FPR pan-antagonist Boc2, or the FPR2/ALX antagonist WRW4) revealed neutrophil FPR2/ALX to be important in this process. CONCLUSIONS AND IMPLICATIONS: Data presented here provide evidence for a role of MCs, which are ideally positioned in close proximity to the vasculature, to act as sentinel cells in neutrophil extravasation and resolution of inflammation via the AnxA1-FPR2/ALX pathway.
[Mh] MeSH terms primary: Anti-Inflammatory Agents/pharmacology
Mast Cells/drug effects
Mast Cells/metabolism
Neutrophil Infiltration/drug effects
Receptors, Formyl Peptide/metabolism
[Mh] MeSH terms secundary: Animals
Annexin A1/chemistry
Annexin A1/pharmacology
Anti-Inflammatory Agents/chemistry
Cromolyn Sodium/chemistry
Cromolyn Sodium/pharmacology
Endothelial Cells/drug effects
Intravital Microscopy
Lipopolysaccharides/chemistry
Lipopolysaccharides/pharmacology
Male
Mice
Mice, Inbred C57BL
Neutrophils/drug effects
Peptides/chemistry
Peptides/pharmacology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Annexin A1); 0 (Anti-Inflammatory Agents); 0 (Fpr1 protein, mouse); 0 (Lipopolysaccharides); 0 (Peptides); 0 (Receptors, Formyl Peptide); 0 (annexin A1 peptide (2-26)); 0 (formyl peptide receptor 2, mouse); Q2WXR1I0PK (Cromolyn Sodium)
[Em] Entry month:1802
[Cu] Class update date: 180216
[Lr] Last revision date:180216
[Js] Journal subset:IM
[Da] Date of entry for processing:170505
[St] Status:MEDLINE
[do] DOI:10.1111/bph.13847

  4 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29241053
[Au] Autor:Kesa P; Jancura D; Kudlácová J; Valusová E; Antalík M
[Ad] Address:Department of Biophysics, Institute of Experimental Physics, Slovak Academy of Sciences, Watsonova 47, 040 01 Kosice, Slovakia. Electronic address: kesa@saske.sk.
[Ti] Title:Excitation of triplet states of hypericin in water mediated by hydrotropic cromolyn sodium salt.
[So] Source:Spectrochim Acta A Mol Biomol Spectrosc;193:185-191, 2018 Mar 15.
[Is] ISSN:1873-3557
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Hypericin (Hyp) is a hydrophobic pigment found in plants of the genus Hypericum which exhibits low levels of solubility in water. This work shows that the solubility of Hyp can be significantly increased through the addition of cromolyn disodium salt (DSCG). Performed studies using UV-VIS absorption and fluorescence spectroscopies demonstrate that Hyp remains in a predominantly biologically photodynamic active monomeric form in the presence of DSCG at concentrations ranging from 4.6×10 to 1.2×10 mol·L . The low association constant between Hyp and DSCG (K =71.7±2M ), and the polarity value of 0.3 determined for Hyp in a DSCG-water solution, lead to a suggestion that the monomerization of Hyp in aqueous solution can be explained as a result of the hydrotropic effect of DSCG. This hydrotropic effect is most likely a result of interactions between two relative rigid aromatic rings of DSCG and a delocalized charge on the surface of the Hyp molecule. The triplet-triplet (T-T) electronic transition observed in is Hyp in the presence of DSCG suggests a possible production of reactive oxygen species once Hyp is irradiated with visible light in a DSCG aqueous solution.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180207
[Lr] Last revision date:180207
[St] Status:In-Process

  5 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29348604
[Au] Autor:Zhang C; Griciuc A; Hudry E; Wan Y; Quinti L; Ward J; Forte AM; Shen X; Ran C; Elmaleh DR; Tanzi RE
[Ad] Address:Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129-2060, USA.
[Ti] Title:Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid ß-Protein by Promoting Microglial Phagocytosis.
[So] Source:Sci Rep;8(1):1144, 2018 Jan 18.
[Is] ISSN:2045-2322
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Amyloid-beta protein (Aß) deposition is a pathological hallmark of Alzheimer's disease (AD). Aß deposition triggers both pro-neuroinflammatory microglial activation and neurofibrillary tangle formation. Cromolyn sodium is an asthma therapeutic agent previously shown to reduce Aß levels in transgenic AD mouse brains after one-week of treatment. Here, we further explored these effects as well as the mechanism of action of cromolyn, alone, and in combination with ibuprofen in APP -expressing Tg2576 mice. Mice were treated for 3 months starting at 5 months of age, when the earliest stages of ß-amyloid deposition begin. Cromolyn, alone, or in combination with ibuprofen, almost completely abolished longer insoluble Aß species, i.e. Aß40 and Aß42, but increased insoluble Aß38 levels. In addition to its anti-aggregation effects on Aß, cromolyn, alone, or plus ibuprofen, but not ibuprofen alone, increased microglial recruitment to, and phagocytosis of ß-amyloid deposits in AD mice. Cromolyn also promoted Aß42 uptake in microglial cell-based assays. Collectively, our data reveal robust effects of cromolyn, alone, or in combination with ibuprofen, in reducing aggregation-prone Aß levels and inducing a neuroprotective microglial activation state favoring Aß phagocytosis versus a pro-neuroinflammatory state. These findings support the use of cromolyn, alone, or with ibuprofen, as a potential AD therapeutic.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180128
[Lr] Last revision date:180128
[St] Status:In-Data-Review
[do] DOI:10.1038/s41598-018-19641-2

  6 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 28832739
[Au] Autor:Müller EG; Santos MSD; Freitas D; Gomes JÁP; Belfort R
[Ad] Address:Department of Ophthalmology and Visual Sciences, Universidade Federal de São Paulo, São Paulo, Brazil.
[Ti] Title:Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial.
[So] Source:Arq Bras Oftalmol;80(3):154-158, 2017 Jun.
[Is] ISSN:1678-2925
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:PURPOSE: To assess the efficacy of monotherapy using tacrolimus eye drops versus sodium cromoglycate for the treatment of vernal keratoconjunctivitis (VKC). METHODS: Randomized double-masked controlled trial comparing the efficacy of tacrolimus 0.03% eye drops t.i.d. (Group 1) with sodium cromoglycate 4% eye drops t.i.d. (Group 2) for the symptomatic control of VKC at days 0, 15, 30, 45, and 90 of follow-up. Visual acuity, intraocular pressure, and other complications were evaluated to assess safety and side effects. RESULTS: In total, 16 patients were included, with 8 enrolled in each group. Two patients from Group 2 were excluded from the analysis at days 45 and 90 because of corticosteroid use. Most patients were male (81.8%) and presented with limbal VKC (56.3%). There were statistically significant differences in favor of tacrolimus in the following severity scores: itching at day 90 (p=0.001); foreign body sensation at day 15 (p=0.042); photophobia at day 30 (p=0.041); keratitis at day 30 (p=0.048); and limbal activity at days 15 (p=0.011), 30 (p=0.007), and 45 (p=0.015). No relevant adverse effects were reported, except for a burning sensation with tacrolimus, though this did not compromise treatment compliance. CONCLUSION: Treatment with tacrolimus was superior to sodium cromoglycate when comparing severity scores for symptoms of itching, foreign body sensation, and photophobia, as well as for signs of limbal inflammatory activity and keratitis.
[Mh] MeSH terms primary: Conjunctivitis, Allergic/drug therapy
Immunosuppressive Agents/therapeutic use
Tacrolimus/therapeutic use
[Mh] MeSH terms secundary: Adolescent
Child
Conjunctivitis, Allergic/pathology
Cromolyn Sodium/therapeutic use
Double-Blind Method
Female
Humans
Male
Ophthalmic Solutions/therapeutic use
Severity of Illness Index
Statistics, Nonparametric
Time Factors
Treatment Outcome
Visual Acuity
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Name of substance:0 (Immunosuppressive Agents); 0 (Ophthalmic Solutions); Q2WXR1I0PK (Cromolyn Sodium); WM0HAQ4WNM (Tacrolimus)
[Em] Entry month:1709
[Cu] Class update date: 170925
[Lr] Last revision date:170925
[Js] Journal subset:IM
[Da] Date of entry for processing:170824
[St] Status:MEDLINE

  7 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28831114
[Au] Autor:Zhu H; Wang X; Huang M; Jing Y; Zhang D; Ding G
[Ad] Address:Department of Aeronautics and Astronautics, Fudan University, Shanghai, 200433, China.
[Ti] Title:Mast cell activation in the acupoint is important for the electroacupuncture effect against pituitrin-induced bradycardia in rabbits.
[So] Source:Sci Rep;7(1):9040, 2017 Aug 22.
[Is] ISSN:2045-2322
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:This research was conducted to verify the structural and functional characteristics of mast cells in the electroacupuncture (EA) effects on bradycardia. First, we examined the mast cell density at PC 6, adjacent acupoint LU 7, and a non-acupoint. We tested the effects of EA at PC 6 on heart rate (HR) and blood pressure (BP) in rabbits with pituitrin-induced bradycardia. We also injected sodium cromolyn (Cro), a mast cell membrane stabilizer, at PC 6 30 min before EA to investigate if it affected the EA effects. The results showed that in both PC 6 and LU 7, the mast cell densities were higher than in the non-acupoint (P < 0.05). EA could induce mast cell degranulation at PC 6, which could be suppressed by sodium cromolyn (P < 0.05). EA improved HR, though the change was relatively small in the initial stage with a significant change at 35 min after modelling (P < 0.05). BP significantly improved at 10 min after the onset of pituitrin-induced bradycardia (P < 0.05). The EA effects on both HR and BP were suppressed by sodium cromolyn (P < 0.05). Therefore, we concluded that mast cells in the acupoint are important for the EA effects against pituitrin-induced bradycardia in rabbits.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1708
[Cu] Class update date: 170903
[Lr] Last revision date:170903
[St] Status:In-Data-Review
[do] DOI:10.1038/s41598-017-08855-5

  8 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28733146
[Au] Autor:Huang X; Zhao W; Hu D; Han X; Wang H; Yang J; Xu Y; Li Y; Yao W; Chen C
[Ad] Address:Department of Anesthesiology, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University. Shenzhen, China.
[Ti] Title:Resveratrol efficiently improves pulmonary function via stabilizing mast cells in a rat intestinal injury model.
[So] Source:Life Sci;185:30-37, 2017 Sep 15.
[Is] ISSN:1879-0631
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND: Intestinal ischemia/reperfusion (IIR) leads to acute lung injury (ALI) distally by aggravating pulmonary oxidative stress. Resveratrol is effective in attenuating ALI through its antioxidant capacity. This study aimed to determine the effects of resveratrol on IIR-induced ALI and to explore the role of mast cells (MCs) activation in a rat model of IIR. METHODS: Adult Sprague-Dawley rats were subjected to IIR by occluding the superior mesenteric artery for 60min followed by 4-hour reperfusion. Resveratrol was intraperitoneally injected at a dose of 15mg/kg for 5days before IIR. MCs stabilizer/inhibitor cromolyn sodium and degranulator compound 48/80 were used to explore the interaction between resveratrol and MCs. Lung tissues were collected for pathological detection and MCs staining. Pulmonary protein expression of surfactant protein-C (SP-C), tryptase, p47 and gp91 (two NADPH oxidase subunits), ICAM-1(intercellular adhesion molecule-1) and P-selectin were detected. The levels of oxidative stress markers (SOD, MDA, H O and MPO) and ß-hexosaminidase were also measured. RESULTS: At the end of IIR, lung injury was significantly increased and was associated with decreased expression of SP-C and increased lung oxidative stress. Increased inflammation as well as activation of MCs was also observed in the lungs after IIR. All these changes were prevented or reversed by resveratrol pretreatment or MCs inhibition with cromolyn sodium. However, these protective effects of resveratrol or cromolyn sodium were reduced by MCs degranulator compound 48/80. CONCLUSIONS: These findings reveal that resveratrol attenuates IIR-induced ALI by reducing NADPH oxidase protein expression and inflammation through stabilizing MCs.
[Mh] MeSH terms primary: Acute Lung Injury/drug therapy
Intestinal Diseases/drug therapy
Mast Cells/drug effects
Reperfusion Injury/drug therapy
Stilbenes/pharmacology
[Mh] MeSH terms secundary: Acute Lung Injury/etiology
Animals
Antioxidants/pharmacology
Disease Models, Animal
Intestinal Diseases/complications
Male
Mast Cells/metabolism
NADPH Oxidases/metabolism
Oxidative Stress/drug effects
Rats
Rats, Sprague-Dawley
Reperfusion Injury/complications
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antioxidants); 0 (Stilbenes); EC 1.6.3.- (NADPH Oxidases); Q369O8926L (resveratrol)
[Em] Entry month:1709
[Cu] Class update date: 171116
[Lr] Last revision date:171116
[Js] Journal subset:IM
[Da] Date of entry for processing:170723
[St] Status:MEDLINE

  9 / 4336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28732690
[Au] Autor:Motawi TK; El-Maraghy SA; ElMeshad AN; Nady OM; Hammam OA
[Ad] Address:Biochemistry Department, Faculty of Pharmacy, Cairo University, Kasr El Ainy st., Cairo 11562, Egypt. Electronic address: tarek.motawi@pharma.cu.edu.eg.
[Ti] Title:Cromolyn chitosan nanoparticles as a novel protective approach for colorectal cancer.
[So] Source:Chem Biol Interact;275:1-12, 2017 Sep 25.
[Is] ISSN:1872-7786
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:Colorectal cancer is the third most common cancer in the world. Cromolyn is a mast cell stabilizer and was proposed as an anticancer agent; however its high polarity limits its bioavailability by rapid washing from the body. We formulated 10 cromolyn chitosan nanoparticles (CCSNPs) following ionic gelation technique to improve its bioavailability and investigated the protective anticancer effect of the optimum formula against colorectal cancer in dimethylhydrazine-induced model in rats. Rats were divided into seven groups, group-1: normal control, group-2: cromolyn control, group-3: CCSNPs control, groups-4 to 7 received dimethylhydrazine for 16 weeks to induce colorectal cancer. Groups-5 to 7 received cromolyn solution, non-medicated chitosan nanoparticles and CCSNPs, respectively as protective treatments. Optimum CCSNPs (size 112.4 nm, charge +39.9 mV, enclosed 93.6% cromolyn and showed a sustained drug release pattern over 48 h) significantly reduced tumor-signaling molecules and the number of aberrant crypt foci compared to dimethylhydrazine. Histopathological examination of colon samples revealed that CCSNPs exerted an augmented protective anticancer effect by ameliorating tumor pathology compared to cromolyn solution. In conclusion, CCSNPs ameliorated tumor pathology and malignant oncogenic signaling molecules in colorectal cancer tissue. Thus, CCSNPs may provide a novel protective approach in colorectal cancer treatment. Moreover, encapsulating cromolyn in chitosan nanoparticles augmented the protective anticancer effect of the drug.
[Mh] MeSH terms primary: Chitosan/chemistry
Cromolyn Sodium/chemistry
Cromolyn Sodium/pharmacology
Nanoparticles/chemistry
[Mh] MeSH terms secundary: Animals
Antineoplastic Agents/chemistry
Antineoplastic Agents/pharmacology
Antineoplastic Agents/therapeutic use
Colorectal Neoplasms/chemically induced
Colorectal Neoplasms/drug therapy
Colorectal Neoplasms/pathology
Cromolyn Sodium/therapeutic use
Dimethylhydrazines/toxicity
Drug Carriers/chemistry
Drug Liberation
Lipid Peroxidation/drug effects
Male
Particle Size
Proto-Oncogene Proteins c-akt/metabolism
Proto-Oncogene Proteins c-bcl-2/metabolism
Rats
Rats, Wistar
Signal Transduction/drug effects
beta Catenin/metabolism
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (Dimethylhydrazines); 0 (Drug Carriers); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (beta Catenin); 9012-76-4 (Chitosan); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); Q2WXR1I0PK (Cromolyn Sodium)
[Em] Entry month:1709
[Cu] Class update date: 170926
[Lr] Last revision date:170926
[Js] Journal subset:IM
[Da] Date of entry for processing:170723
[St] Status:MEDLINE

  10 / 4336 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28720208
[Au] Autor:Simonsen E; Komenda P; Lerner B; Askin N; Bohm C; Shaw J; Tangri N; Rigatto C
[Ad] Address:Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
[Ti] Title:Treatment of Uremic Pruritus: A Systematic Review.
[So] Source:Am J Kidney Dis;70(5):638-655, 2017 Nov.
[Is] ISSN:1523-6838
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients. The optimal treatments for uremic pruritus are not well defined. STUDY DESIGN: Systematic review. SETTING & POPULATION: Adult patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. SELECTION CRITERIA FOR STUDIES: PubMed, CINAHL, Embase, International Pharmaceutical Abstracts, Scopus, Cochrane Library, and ClinicalTrials.gov from their inception to March 6, 2017, were systematically searched for randomized controlled trials (RCTs) of uremic pruritus treatments in patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. 2 reviewers extracted data independently. Risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. INTERVENTION: Any intervention for the treatment of uremic pruritus was included. OUTCOMES: A quantitative change in pruritus intensity on a visual analogue, verbal rating, or numerical rating scale. RESULTS: 44 RCTs examining 39 different treatments were included in the review. These treatments included gabapentin, pregabalin, mast cell stabilizers, phototherapy, hemodialysis modifications, and multiple other systemic and topical treatments. The largest body of evidence was found for the effectiveness of gabapentin. Due to the limited number of trials for the other treatments included, we are unable to comment on their efficacy. Risk of bias in most studies was high. LIMITATIONS: Heterogeneity in design, treatments, and outcome measures rendered comparisons difficult and precluded meta-analysis. CONCLUSIONS: Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak. Large, simple, rigorous, multiarm RCTs of promising therapies are urgently needed.
[Mh] MeSH terms primary: Analgesics/therapeutic use
Anti-Asthmatic Agents/therapeutic use
Antipruritics/therapeutic use
Phototherapy/methods
Pruritus/therapy
Renal Dialysis/methods
Renal Insufficiency, Chronic/complications
Uremia/complications
[Mh] MeSH terms secundary: Administration, Cutaneous
Amines/therapeutic use
Capsaicin/therapeutic use
Cromolyn Sodium/therapeutic use
Cyclohexanecarboxylic Acids/therapeutic use
Humans
Kidney Failure, Chronic/complications
Kidney Failure, Chronic/therapy
Pregabalin/therapeutic use
Pruritus/etiology
gamma-Aminobutyric Acid/therapeutic use
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Amines); 0 (Analgesics); 0 (Anti-Asthmatic Agents); 0 (Antipruritics); 0 (Cyclohexanecarboxylic Acids); 55JG375S6M (Pregabalin); 56-12-2 (gamma-Aminobutyric Acid); 6CW7F3G59X (gabapentin); Q2WXR1I0PK (Cromolyn Sodium); S07O44R1ZM (Capsaicin)
[Em] Entry month:1710
[Cu] Class update date: 171030
[Lr] Last revision date:171030
[Js] Journal subset:IM
[Da] Date of entry for processing:170720
[St] Status:MEDLINE


page 1 of 434 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information